{"id":"NCT01332019","sponsor":"Biogen","briefTitle":"Long-Term Safety and Efficacy Study of Peginterferon Beta-1a","officialTitle":"A Dose-Frequency Blinded, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-04","primaryCompletion":"2015-10","completion":"2015-10","firstPosted":"2011-04-08","resultsPosted":"2017-01-13","lastUpdate":"2017-01-13"},"enrollment":1077,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Relapsing Multiple Sclerosis"],"interventions":[{"type":"DRUG","name":"peginterferon beta-1a","otherNames":["PEGylated Interferon beta-1a","Plegridy","PEG IFN Î²-1a","BIIB017"]}],"arms":[{"label":"peginterferon beta-1a Q4W","type":"EXPERIMENTAL"},{"label":"peginterferon beta-1a Q2W","type":"EXPERIMENTAL"}],"summary":"The primary objective of this study is to evaluate the long-term safety and tolerability of peginterferon beta-1a (BIIB017) in participants originally treated in Study 105MS301 (NCT00906399) who continue peginterferon beta-1a treatment. The secondary objective of this study is to describe long-term multiple sclerosis (MS) outcomes in participants originally treated in Study 105MS301 (NCT00906399) who continue peginterferon beta-1a treatment.","primaryOutcome":{"measure":"Number of Participants Experiencing Adverse Events (AEs) Serious AEs, and Discontinuations Due to AEs","timeFrame":"up to 4 years","effectByArm":[{"arm":"BIIB017 Q4W","deltaMin":471,"sd":null},{"arm":"BIIB017 Q2W","deltaMin":478,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":3},"locations":{"siteCount":151,"countries":["United States","Belgium","Bulgaria","Canada","Chile","Colombia","Croatia","Czechia","Estonia","France","Georgia","Germany","Greece","India","Latvia","Mexico","Netherlands","New Zealand","Peru","Poland","Romania","Russia","Serbia","Spain","Ukraine","United Kingdom"]},"refs":{"pmids":["30181780","25073663"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":114,"n":529},"commonTop":["Influenza like illness","Injection site erythema","Headache","Multiple sclerosis relapse","Pyrexia"]}}